Introduction: A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence that their clinical evidence, pricing expectations, and value communication would withstand payer scrutiny. The therapy showed strong early promise,... Continue reading
Return to previous page
Page 2
Introduction: During 2024, a mid-sized biopharma company from the European region was developing a novel systematic therapy for the treatment of IPF, seeking an evidence-backed structured partnership strategy, where EpiLansis played an instrumental role in validating the market assumptions, estimating the market potential, and identifying... Continue reading
Introduction: The pharma ecosystem is quite complex, wherein companies operate across various channels, ranging from hospital procurement networks to retail pharmacies. While this expands their market reach, it also creates challenges in forecasting demand because of fragmented data sources, channel silos, and inconsistent demand visibility.... Continue reading
Background: In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hundreds of potential cancers and limited resources, selecting the most promising therapeutic indications for early-stage assets is both critical... Continue reading
Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company’s growth trajectory, especially in emerging markets where potential is enormous but super fragmented. Our biopharma client, a global player aiming... Continue reading
Background: Launching a new therapy in the oncology space is one of the most complex and challenging in the pharma and biotech industries. With evolving treatment landscapes, shifting market dynamics, and diverse patient journeys across geographies, forecasting future uptake has never been straightforward. One of... Continue reading
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not always capture the full gamut of patient experience, follow-up behavior, and the long-term impact of standard-of-care practices observed in real-world... Continue reading
Introduction: In today’s competitive pharmaceutical industry, success relies on anticipating market changes. With rapidly growing data sources, AI-powered data analytics solutions, and predictive modeling, organizations are commanded to stay ahead of the competition. The Challenge: Pharma companies rely heavily on retrospective market research — analyzing... Continue reading
Introduction: In today’s dynamic pharmaceutical landscape, the need for seamless data access and faster decision-making has made AI-powered, cloud-based solutions a cornerstone of innovation. As a pharma company that works across multiple therapy areas simultaneously, traditional data silos have proven inefficient for providing insights into... Continue reading
Introduction: Drug discovery is a complicated, time-intensive, and expensive undertaking, fraught with vast uncertainty. Even with advancements in science and technology, many drug development programs continue to fail, mainly due to safety and efficacy issues. It takes over $2.5 billion and 8 to 10 years... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
